{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:53:30Z","timestamp":1793116410640,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Joint scientific research fund projects of public hospitals","award":["2024GLLH0125"],"award-info":[{"award-number":["2024GLLH0125"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00228-025-03882-y","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:03:50Z","timestamp":1753988630000},"page":"1493-1506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of insulin sensitisers for treating type 2 diabetes: a network meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Gerile","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuQi","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiduo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"3882_CR1","first-page":"101","volume":"44","author":"S Wenwen","year":"2021","unstructured":"Wenwen S (2021) Analysis of the efficacy of Humalog Mix 25 combined with insulin sensitizers in the treatment of type 2 diabetes. Heilongjiang Med Pharm 44:101\u2013102","journal-title":"Heilongjiang Med Pharm"},{"key":"3882_CR2","first-page":"50","volume":"30","author":"Z Weili","year":"2020","unstructured":"Weili Z (2020) Analysis of the efficacy of \u03b1-glucosidase inhibitors combined with insulin sensitizers in the treatment of type 2 diabetes. J Shanxi Health Vocat Coll 30:50\u201351","journal-title":"J Shanxi Health Vocat Coll"},{"key":"3882_CR3","first-page":"225","volume":"4","author":"L Yi","year":"2010","unstructured":"Yi L, Zhenlin L (2010) Research progress on insulin sensitizers. Chin J Mod Drug Appl 4:225\u2013226","journal-title":"Chin J Mod Drug Appl"},{"key":"3882_CR4","doi-asserted-by":"publisher","first-page":"e051023221768","DOI":"10.2174\/0115733998261903230921102620","volume":"20","author":"A Kumar","year":"2024","unstructured":"Kumar A, Mazumder R, Rani A, Pandey P, Khurana N (2024) Novel approaches for the management of type 2 diabetes mellitus: an update. Curr Diabetes Rev 20. https:\/\/doi.org\/10.2174\/0115733998261903230921102620","journal-title":"Curr Diabetes Rev"},{"key":"3882_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s11596-023-2760-3","volume":"43","author":"XH Zhang","year":"2023","unstructured":"Zhang XH, Tian YF, Huang GL, Cui WY, Sun Q, He WJ, Liu XJ (2023) Advances in studies of chiglitazar sodium, a novel PPAR pan-agonist, for the treatment of type 2 diabetes mellitus. Curr Med Sci 43:890\u2013896. https:\/\/doi.org\/10.1007\/s11596-023-2760-3","journal-title":"Curr Med Sci"},{"key":"3882_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65:1925\u20131966. https:\/\/doi.org\/10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"key":"3882_CR7","unstructured":"Chinese diabetes society (2021) In: Guidelines for the prevention and treatment of type 2 diabetes mellitus in China, 2020 edn. Chin J Diabetes Mellitus 13, 315\u2013409"},{"key":"3882_CR8","doi-asserted-by":"publisher","unstructured":"Green S, Higgins JP (2008) Preparing a Cochrane review. In: Higgins JP, Green S (eds) Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. John Wiley & Sons, Limited, Chichester, pp 11\u201330. https:\/\/doi.org\/10.1002\/9780470712184.ch2","DOI":"10.1002\/9780470712184.ch2"},{"key":"3882_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","volume":"19","author":"A B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau A, Boyne DJ, Slater J, Brenner D, Arora P (2019) BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med Res Methodol 19:196. https:\/\/doi.org\/10.1186\/s12874-019-0829-2","journal-title":"BMC Med Res Methodol"},{"key":"3882_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00273171.2022.2115965","volume":"58","author":"Y Liu","year":"2023","unstructured":"Liu Y, B\u00e9liveau A, Wei Y, Chen MY, Record-Lemon R, Kuo PL, Pritchard E, Tang X, Chen G (2023) A gentle introduction to Bayesian network meta-analysis using an automated R package. Multivar Behav Res 58:706\u2013722. https:\/\/doi.org\/10.1080\/00273171.2022.2115965","journal-title":"Multivar Behav Res"},{"key":"3882_CR11","doi-asserted-by":"publisher","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ (2018) Network meta\u2010analysis for decision making, 1st edn. John Wiley & Sons. https:\/\/doi.org\/10.1002\/9781118951651","DOI":"10.1002\/9781118951651"},{"key":"3882_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98\u2013110. https:\/\/doi.org\/10.1002\/jrsm.1044","journal-title":"Res Synth Methods"},{"key":"3882_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE (2013) Evidence synthesis for decision making 3: heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making 33:618\u2013640. https:\/\/doi.org\/10.1177\/0272989X13485157","journal-title":"Med Decis Making"},{"key":"3882_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2021.07.011","volume":"139","author":"R Brignardello-Petersen","year":"2021","unstructured":"Brignardello-Petersen R, Guyatt GH, Mustafa RA et al (2021) GRADE guidelines 33: addressing imprecision in a network meta-analysis. J Clin Epidemiol 139:49\u201356","journal-title":"J Clin Epidemiol"},{"key":"3882_CR15","first-page":"334","volume":"11","author":"X L\u00fc","year":"2019","unstructured":"L\u00fc X, Gao Y, Zhu L et al (2019) Efficacy and safety of chiglitazar sodium in patients with type 2 diabetes: a multicenter, randomized, double-blind, parallel-controlled clinical trial. Chin J Diabetes 11:334\u2013340","journal-title":"Chin J Diabetes"},{"key":"3882_CR16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","volume":"66","author":"L Ji","year":"2021","unstructured":"Ji L, Song W, Fang H, Li W, Geng J, Wang Y, Guo L, Cai H, Yang T, Li H, Yang G, Li Q, Liu K, Li S, Liu Y, Shi F, Li X, Gao X, Tian H, Ji Q, Su Q, Zhou Z, Wang W, Zhou Z, Li X, Xu Y, Ning Z, Cao H, Pan D, Yao H, Lu X, Jia W (2021) Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Sci Bull (Beijing) 66:1571\u20131580. https:\/\/doi.org\/10.1016\/j.scib.2021.03.019","journal-title":"Sci Bull (Beijing)"},{"key":"3882_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","volume":"66","author":"W Jia","year":"2021","unstructured":"Jia W, Ma J, Miao H, Wang C, Wang X, Li Q, Lu W, Yang J, Zhang L, Yang J, Wang G, Zhang X, Zhang M, Sun L, Yu X, Du J, Shi B, Xiao C, Zhu D, Liu H, Zhong L, Xu C, Xu Q, Liang G, Zhang Y, Li G, Gu M, Liu J, Yuan G, Yan Z, Yan D, Ye S, Zhang F, Ning Z, Cao H, Pan D, Yao H, Lu X, Ji L (2021) Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Sci Bull (Beijing) 66:1581\u20131590. https:\/\/doi.org\/10.1016\/j.scib.2021.02.027","journal-title":"Sci Bull (Beijing)"},{"key":"3882_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/pedi.13279","volume":"23","author":"RR Shankar","year":"2022","unstructured":"Shankar RR, Zeitler P, Deeb A, Jalaludin MY, Garcia R, Newfield RS, Samoilova Y, Rosario CA, Shehadeh N, Saha CK, Zhang Y, Zilli M, Scherer LW, Lam RLH, Golm GT, Engel SS, Kaufman KD (2022) A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatr Diabetes 23:173\u2013182. https:\/\/doi.org\/10.1111\/pedi.13279","journal-title":"Pediatr Diabetes"},{"key":"3882_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/pedi.12790","volume":"20","author":"IP Fraser","year":"2019","unstructured":"Fraser IP, Neufeld ND, Fox LA, Kipnes MS, Miller TL, Zeitler PS, Rodriguez H, Gilmartin JH, Lee SJ, Patterson JK, Li XS, Maganti L, Luo WL, Tatosian DA, Stoch SA (2019) A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. Pediatr Diabetes 20:48\u201356. https:\/\/doi.org\/10.1111\/pedi.12790","journal-title":"Pediatr Diabetes"},{"key":"3882_CR20","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Study S 021 Group (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632\u20132637. https:\/\/doi.org\/10.2337\/dc06-0703","journal-title":"Diabetes Care"},{"key":"3882_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1185\/03007995.2011.568059","volume":"27","author":"N Barzilai","year":"2011","unstructured":"Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H (2011) Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 27:1049\u20131058. https:\/\/doi.org\/10.1185\/03007995.2011.568059","journal-title":"Curr Med Res Opin"},{"key":"3882_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165:305\u2013315. https:\/\/doi.org\/10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"3882_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/MEG.0000000000000780","volume":"29","author":"XL Deng","year":"2017","unstructured":"Deng XL, Ma R, Zhu HX, Zhu J (2017) A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 29:297\u2013301. https:\/\/doi.org\/10.1097\/MEG.0000000000000780","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3882_CR24","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","volume":"49","author":"I Raz","year":"2006","unstructured":"Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, Study S 023 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564\u20132571. https:\/\/doi.org\/10.1007\/s00125-006-0416-z","journal-title":"Diabetologia"},{"key":"3882_CR25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1185\/030079907X188152","volume":"23","author":"M Hanefeld","year":"2007","unstructured":"Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP, Sitagliptin Study 014 Investigators (2007) Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 23:1329\u20131339. https:\/\/doi.org\/10.1185\/030079907X188152","journal-title":"Curr Med Res Opin"},{"key":"3882_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1185\/03007995.2012.694361","volume":"28","author":"M Kikuchi","year":"2012","unstructured":"Kikuchi M, Kaku K, Odawara M, Momomura S, Ishii R (2012) Efficacy and tolerability of rosiglitazone and pioglitazone in drug-na\u00efve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks\u2019 treatment, comparative study. Curr Med Res Opin 28:1007\u20131016. https:\/\/doi.org\/10.1185\/03007995.2012.694361","journal-title":"Curr Med Res Opin"},{"key":"3882_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1507\/endocrj.k09e-272","volume":"57","author":"Y Iwamoto","year":"2010","unstructured":"Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J (2010) Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 57:383\u2013394. https:\/\/doi.org\/10.1507\/endocrj.k09e-272","journal-title":"Endocr J"},{"key":"3882_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.diabres.2008.10.009","volume":"83","author":"V Mohan","year":"2009","unstructured":"Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD (2009) Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 83:106\u2013116. https:\/\/doi.org\/10.1016\/j.diabres.2008.10.009","journal-title":"Diabetes Res Clin Pract"},{"key":"3882_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1055\/s-0028-1100413","volume":"41","author":"K Nonaka","year":"2009","unstructured":"Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM (2009) Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 41:232\u2013237. https:\/\/doi.org\/10.1055\/s-0028-1100413","journal-title":"Horm Metab Res"},{"key":"3882_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.diabres.2007.08.021","volume":"79","author":"K Nonaka","year":"2008","unstructured":"Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP (2008) Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79:291\u2013298. https:\/\/doi.org\/10.1016\/j.diabres.2007.08.021","journal-title":"Diabetes Res Clin Pract"},{"key":"3882_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.cir.0000025403.20953.23","volume":"106","author":"SM Haffner","year":"2002","unstructured":"Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679\u2013684. https:\/\/doi.org\/10.1161\/01.cir.0000025403.20953.23","journal-title":"Circulation"},{"key":"3882_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2337\/diacare.24.2.308","volume":"24","author":"LS Phillips","year":"2001","unstructured":"Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, Rosiglitazone Clinical Trials Study Group (2001) Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24:308\u2013315. https:\/\/doi.org\/10.2337\/diacare.24.2.308","journal-title":"Diabetes Care"},{"key":"3882_CR33","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","volume":"28","author":"RB Goldberg","year":"2005","unstructured":"Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, GLAI Study Investigators (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547\u20131554. https:\/\/doi.org\/10.2337\/diacare.28.7.1547","journal-title":"Diabetes Care"},{"key":"3882_CR34","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/s0149-2918(03)80068-1","volume":"25","author":"M Herz","year":"2003","unstructured":"Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jim\u00e9nez F, Hardin PA, Konkoy CS, Tan MH (2003) A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 25:1074\u20131095. https:\/\/doi.org\/10.1016\/s0149-2918(03)80068-1","journal-title":"Clin Ther"},{"key":"3882_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1055\/s-2002-35421","volume":"34","author":"WA Scherbaum","year":"2002","unstructured":"Scherbaum WA, G\u00f6ke B, German Pioglitazone Study Group (2002) Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 34:589\u2013595. https:\/\/doi.org\/10.1055\/s-2002-35421","journal-title":"Horm Metab Res"},{"key":"3882_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s001250050045","volume":"43","author":"P Raskin","year":"2000","unstructured":"Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278\u2013284. https:\/\/doi.org\/10.1007\/s001250050045","journal-title":"Diabetologia"},{"key":"3882_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1464-5491.2000.00269.x","volume":"17","author":"JJ Nolan","year":"2000","unstructured":"Nolan JJ, Jones NP, Patwardhan R, Deacon LF (2000) Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17:287\u2013294. https:\/\/doi.org\/10.1046\/j.1464-5491.2000.00269.x","journal-title":"Diabet Med"},{"key":"3882_CR38","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","volume":"23","author":"S Aronoff","year":"2000","unstructured":"Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 23:1605\u20131611. https:\/\/doi.org\/10.2337\/diacare.23.11.1605","journal-title":"Diabetes Care"},{"key":"3882_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","volume":"61","author":"R Scott","year":"2007","unstructured":"Scott R, Wu M, Sanchez M, Stein P (2007) Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61:171\u2013180. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01246.x","journal-title":"Int J Clin Pract"},{"key":"3882_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/dom.12145","volume":"15","author":"M Alba","year":"2013","unstructured":"Alba M, Ahr\u00e9n B, Inzucchi SE, Guan Y, Mallick M, Xu L, O\u2019Neill EA, Williams-Herman DE, Kaufman KD, Goldstein BJ (2013) Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes Obes Metab 15:1101\u20131110. https:\/\/doi.org\/10.1111\/dom.12145","journal-title":"Diabetes Obes Metab"},{"key":"3882_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1742-1241.2011.02749.x","volume":"65","author":"A P\u00e9rez-Monteverde","year":"2011","unstructured":"P\u00e9rez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ (2011) Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-na\u00efve patients with type 2 diabetes. Int J Clin Pract 65:930\u2013938. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02749.x","journal-title":"Int J Clin Pract"},{"key":"3882_CR42","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, ESC Scientific Document Group (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44:4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"3882_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED (2022) Chiglitazar: first approval. Drugs 82:87\u201392. https:\/\/doi.org\/10.1007\/s40265-021-01648-1","journal-title":"Drugs"},{"key":"3882_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.4239\/wjd.v14.i10.1573","volume":"14","author":"C Lin","year":"2023","unstructured":"Lin C, Li ZL, Cai XL, Hu SY, Lv F, Yang WJ, Ji LN (2023) Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: a meta-analysis. World J Diabetes 14:1573\u20131584. https:\/\/doi.org\/10.4239\/wjd.v14.i10.1573","journal-title":"World J Diabetes"},{"key":"3882_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross B, Pawlak M, Lefebvre P, Staels B (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13:36\u201349. https:\/\/doi.org\/10.1038\/nrendo.2016.135","journal-title":"Nat Rev Endocrinol"},{"key":"3882_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1503\/cmaj.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180:32\u201339. https:\/\/doi.org\/10.1503\/cmaj.080486","journal-title":"CMAJ"},{"key":"3882_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3780","volume":"40","author":"Y Shen","year":"2024","unstructured":"Shen Y, Shi Q, Zou X, Meng W, Tian H, Du L, Li S (2024) Time-dependent risk of fracture in adults with type 2 diabetes receiving antidiabetic drug: a one-stage network meta-analysis. Diabetes Metab Res Rev 40:e3780. https:\/\/doi.org\/10.1002\/dmrr.3780","journal-title":"Diabetes Metab Res Rev"},{"key":"3882_CR48","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:2461\u20132498. https:\/\/doi.org\/10.1007\/s00125-018-4729-5","journal-title":"Diabetologia"},{"key":"3882_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173:278\u2013286. https:\/\/doi.org\/10.7326\/M20-0864","journal-title":"Ann Intern Med"},{"key":"3882_CR50","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.numecd.2020.12.030","volume":"31","author":"E Mannucci","year":"2021","unstructured":"Mannucci E, Naletto L, Vaccaro G, Silverii A, Dicembrini I, Pintaudi B, Monami M (2021) Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: a network meta-analysis of randomized, active comparator-controlled trials. Nutr Metab Cardiovasc Dis 31:1027\u20131034. https:\/\/doi.org\/10.1016\/j.numecd.2020.12.030","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03882-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03882-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:37:09Z","timestamp":1758091029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03882-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3882"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03882-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}